Employees: 02 (2023.0)Legal category: 5485Size: PMECreation date: 2005-10-01 (20 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: MALESTROIT (56140), Morbihan
SELARL PHARMACIE CRUSSARD : revenue, balance sheet and financial ratios
SELARL PHARMACIE CRUSSARD is a French company
founded 20 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in MALESTROIT (56140),
this company of category PME
shows in 2022 a revenue of 1.4 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - SELARL PHARMACIE CRUSSARD (SIREN 484285697)
Indicator
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
N/C
N/C
1 436 235 €
1 287 635 €
1 329 786 €
N/C
N/C
N/C
N/C
Net income
45 632 €
56 505 €
64 982 €
29 659 €
20 956 €
41 187 €
40 425 €
38 729 €
24 183 €
EBITDA
N/C
N/C
105 136 €
71 555 €
63 438 €
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
4.5%
2.3%
1.6%
N/C
N/C
N/C
N/C
Revenue and income statement
In 2024, SELARL PHARMACIE CRUSSARD generates positive net income of 46 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2024: 24 k€ -> 46 k€.
Net income (2024)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
45 632 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 112%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 40%. The balance between equity and debt is satisfactory.
Debt ratio (2024)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
112.298%
Financial autonomy (2024)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
39.891%
Asset age ratio (2024)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Debt ratio
402.501
319.152
269.743
230.759
195.04
177.565
161.23
133.385
112.298
Financial autonomy
17.194
20.729
23.747
27.157
29.098
31.438
33.019
36.279
39.891
Repayment capacity
None
None
None
None
24.727
17.517
12.105
None
None
Cash flow / Revenue
None%
None%
None%
None%
2.147%
3.021%
4.269%
None%
None%
Sector positioning
Debt ratio
112.32024
2022
2023
2024
Q1: 16.46
Med: 58.47
Q3: 154.89
Average-6 pts over 3 years
In 2024, the debt ratio of SELARL PHARMACIE CRUSSARD (112.30) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
Financial autonomy
39.89%2024
2022
2023
2024
Q1: 28.91%
Med: 49.95%
Q3: 69.47%
Average+7 pts over 3 years
In 2024, the financial autonomy of SELARL PHARMACIE CRUSSARD (39.9%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
Repayment capacity
12.11 years2022
2022
Q1: 1.29 years
Med: 3.55 years
Q3: 6.63 years
Average
In 2022, the repayment capacity of SELARL PHARMACIE CRUSSARD (12.11) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 163.96. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2024)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Liquidity ratio
95.081
88.095
93.131
102.323
92.514
97.775
170.047
167.643
163.963
Interest coverage
None
None
None
None
46.445
35.304
24.83
None
None
Sector positioning
Liquidity ratio
163.962024
2022
2023
2024
Q1: 129.47
Med: 182.13
Q3: 260.78
Average
In 2024, the liquidity ratio of SELARL PHARMACIE CRUSSARD (163.96) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
Interest coverage
24.83x2022
2022
Q1: 0.74x
Med: 2.5x
Q3: 5.15x
Excellent
In 2022, the interest coverage of SELARL PHARMACIE CRUSSARD (24.8x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2024)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2024)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2024)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2024)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution SELARL PHARMACIE CRUSSARD
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2021
2022
2023
2024
Operating WCR
0 €
0 €
0 €
0 €
142 167 €
152 430 €
150 690 €
0 €
0 €
Inventory turnover (days)
0
0
0
0
38
42
43
0
0
Customer payment term (days)
0
0
0
0
4
5
4
0
0
Supplier payment term (days)
0
0
0
0
53
48
47
0
0
Positioning of SELARL PHARMACIE CRUSSARD in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 225 transactions of similar company sales
in 2024,
the value of SELARL PHARMACIE CRUSSARD is estimated at
637 056 €
(range 443 636€ - 953 072€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2024
225 transactions
443k€637k€953k€
637 056 €Range: 443 636€ - 953 072€
NAF 5 année 2024
Valuation method used
Net Income Multiple
45 632 €
×
14.0x
=637 056 €
Range: 443 636€ - 953 073€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 225 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare SELARL PHARMACIE CRUSSARD with other companies in the same sector:
Frequently asked questions about SELARL PHARMACIE CRUSSARD
What is the revenue of SELARL PHARMACIE CRUSSARD ?
The revenue of SELARL PHARMACIE CRUSSARD in 2022 is 1.4 M€.
Is SELARL PHARMACIE CRUSSARD profitable?
Yes, SELARL PHARMACIE CRUSSARD generated a net profit of 46 k€ in 2024.
Where is the headquarters of SELARL PHARMACIE CRUSSARD ?
The headquarters of SELARL PHARMACIE CRUSSARD is located in MALESTROIT (56140), in the department Morbihan.
Where to find the tax return of SELARL PHARMACIE CRUSSARD ?
The tax return of SELARL PHARMACIE CRUSSARD is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does SELARL PHARMACIE CRUSSARD operate?
SELARL PHARMACIE CRUSSARD operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart